Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection

Am J Respir Crit Care Med. 2022 Apr 15;205(8):964-968. doi: 10.1164/rccm.202108-1830LE.

Authors

Lucie Sauerhering^{1

2}, Irina Kuznetsova³, Alexandra Kupke¹, Lars Meier¹, Sandro Halwe¹, Cornelius Rohde¹, Jörg Schmidt¹, Rory E Morty^{3

4}, Olga Danov^{4

5}, Armin Braun^{4

5}, István Vadász^{3

4

6}, Stephan Becker^{1

2}, Susanne Herold^{2

3

4

6}

Affiliations

¹ Philipps University of Marburg Marburg, Germany.
² German Center for Infection Research Braunschweig, Germany.
³ University of Giessen Giessen, Germany.
⁴ German Center for Lung Research Giessen, Germany.
⁵ Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Germany.
⁶ Institute for Lung Health Giessen, Germany.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Cyclosporine* / pharmacology
Cyclosporine* / therapeutic use
Drug Evaluation, Preclinical
Humans
SARS-CoV-2

Substances

Antiviral Agents
Cyclosporine